PRESS
Back to News

FSD Pharma Inc. Announces Appointment of Chief Commercial Officer

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE US/

CSE: HUGE

TORONTO, June 21, 2018 /CNW/ – Thomas Fairfull, President and Chief Executive Officer of FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE), is pleased to announce the appointment of Mr. Michael Ash as the Chief Commercial Officer of FV Pharma Inc. (“FV Pharma”), a wholly-owned subsidiary of the Company.

Michael Ash brings a wealth of pharmaceutical industry expertise to FV Pharma in the areas of domestic and international sales and distribution, product and brand development, and product packaging. In his new role, Michael will leverage his extensive network of retail relationships to develop and grow the Company’s distribution network across Canada, thereby enabling the sale and supply of medical pharmaceutical-grade cannabis on a national basis.

Michael has held various high profile positions in the pharmaceutical industry. From 2015 to 2018, Michael was President of Pharmetics Inc. and was identified by the private equity firm that owned the company as the ideal industry expert capable of rebuilding the business, increasing sales and selling the company in 2018. From 2013 to 2015, Michael was President of NutraLab Canada Ltd. (“NutraLab) where he developed and launched private label brands of vitamins, minerals and supplements for large retailers across the country. From 1997 to 2013, Michael held the role of Senior Vice-President of Sales and Marketing at Pharmetics Inc. where he successfully grew sales of vitamins and over the counter (OTC) products from 15 million to close to 100 million dollars. He was able to accomplish substantial sales growth due to his strong retail relationships allowing the business to become the number one supplier of private label OTC products in Canada. From 1984 to 1995, Michael held progressive sales roles at Apotex Inc., including the role of Managing Director International where he was accountable for developing international distribution networks for the company’s generic drug brands. In his role, Michael travelled extensively around the world to establish joint ventures and distribution channels on behalf of the company. During his tenure, international sales grew to over 50 million dollars. Michael holds a BA in Political Science from McGill University.

About FSD Pharma Inc.

FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. Please visit www.fsdpharma.com for more information.

About FV Pharma

FV Pharma is a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR), Having received its cultivation license on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FV Pharma management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.

Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

Additional Information

Thomas Fairfull
Chief Executive Director, FSD Pharma Inc.
[email protected]

Neither the Canadian Securities Exchange nor its regulations services accept responsibility for the adequacy or accuracy of this release.

SOURCE FSD Pharma Inc.

For further information: Investor Relations, Email: [email protected], Website: www.fsdpharma.com